Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared with Originator Insulin Glargine (Lantus®) in Patients with Type 1 Diabetes after 26 Weeks Treatment

Update your browser to view ScienceDirect.

Request details:

Request ID: 8932bf9f6fe01692-SJC
IP: 116.62.10.13
UTC time: 2024-06-13T14:25:11+00:00
Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4